Anna Tomczyk

Anna Tomczyk represents issuers and underwriters on public and private securities offerings, including initial public offerings (IPOs), secondary offerings, confidentially marketed public offerings (CMPOs), at-the-market (ATM) financings, registered direct offerings and PIPEs, as well as Rule 144A and Regulation S offerings. Ms. Tomczyk’s practice also covers a diverse range of complex transactions including mergers and acquisitions, financial restructuring, liability management and other complex strategic transactions. She also acts as a day-to-day advisor for a wide range of public and private clients, providing strategic advice and guidance on corporate governance and strategy, periodic reporting, securities regulation and stock exchange compliance throughout a company’s entire life cycle. She counsels clients from a wide variety of industries, including life sciences, crypto and fintech, financial services and retail.

Select Medical Holdings Corporation, a leading operator of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers, and Concentra Group Holdings Parent, Inc., a wholly owned subsidiary of Select Medical, in connection with Concentra’s IPO.
21Shares and ARK Invest on the launch of their first Bitcoin ETP
21Shares on the launch of their first Ethereum ETP
Aquestive Therapeutics, a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products to address unmet medical needs, in its US$75 million CMPO.
Femasys Inc., a clinical-stage medical device company, in its initial public offering.
The ad hoc group of secured and unsecured bondholders of Brazil’s largest domestic airline, GOL Linhas Aéreas Inteligentes S.A., in connection with its US$1.6 billion combined liability management and new capital financing transaction.
TAG Holdings Limited in its SPAC business combination with AGBA Acquisition Limited
BioAtla, Inc. (Nasdaq: “BCAB”) in its US$189 million initial public offering (with J.P. Morgan, Jefferies and Credit Suisse acting as joint book-running managers).
VIA optronics AG, a leading supplier of enhanced display solutions, in its US$93.75 million cross- border initial public offering and listing on the NYSE.
Acacia Research Corporation (Nasdaq: "ACTG") in connection with its strategic partnership with Starboard Value, consisting of a financing providing Acacia with access to up to US$400 million of new capital for strategic investments and acquisitions.
B&G Foods in connection with its registered public offering of US$550 million in aggregate principal amount of 5.25% senior notes due 2027.
Zyla Life Sciences in its merger with Assertio Therapeutics, Inc.
Sales Agents in multiple At-The-Market offerings by Inovio Pharmaceuticals, Inc., a clinical stage company developing active DNA immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases.
OraSure Technologies, Inc. in its US$95 million public offering of common stock.
The underwriters in connection with Repro Med Systems, Inc. d/b/a KORU Medical Systems (Nasdaq: KRMD)’s US$25 million public offering of common stock.
Cowen and Company, as underwriter, in the US$97 million initial public offering of Boston Omaha Corporation.
Minerva Neurosciences Inc. in its US$32 million initial public offering.
Piper Jaffray, as managing underwriter, in the US$40 million initial public offering of Tengion Inc.
Cowen and Company, as lead underwriter, in a US$55 million follow-on offering for TherapeuticsMD, Inc.
Cowen and Company, as lead underwriter, in US$15 million and US$30 million follow-on offerings for Trillium Therapeutics.
Cowen and Company, as sales agent, in at-the-market offerings for Amicus Therapeutics, Boston Omaha Corporation, Kempharm Inc., and Trillium Therapeutics Inc.
Stifel, Nicolaus & Company, as lead underwriter, in a US$30 million follow-on offering for TherapeuticsMD, Inc.
RBC Capital Markets LLC, as lead underwriter, in a US$25 million follow-on offering for Kempharm Inc.
RBC Capital Markets LLC, as sales agent, in an at-the-market offering for Kempharm Inc.
The initial purchasers in a US$225 million offering of convertible senior notes for Amicus Therapeutics.
Anterios Inc. on its sale to Allergan.
A fishing supply company in its US$330 million high yield note offering.
Rexnord Corporation, in its US$500 million high yield note offering.
A mass customization conglomerate in its US$400 million senior note offering.
The underwriters, including Credit Suisse, Deutsche Bank, Goldman Sachs, J.P. Morgan, Morgan Stanley, UBS and Wells Fargo, in follow-on offerings of common stock and preferred stock of numerous international shipping and oil & gas companies, including Baltic Trading, Box Ships, Costamare, Dryships, Excel Maritime, GasLog, Ocean Rig, Safe Bulkers and Scorpio Bulkers.
Jefferies, on securities law aspects of its US$10 billion merger of equals with Leucadia National Corporation.

Includes matters handled at Dechert or prior to joining the firm.